Published in Oncology Business Week, July 16th, 2006
Scientists in China report, "As a novel member of the IAP family, survivin was observed to express in the most common human cancers. Anticancer therapy targeting survivin has drawn considerable attention. This report presented firstly construction of recombinant plasmid pRSET-B-TAT-survivin (T34A), expression in Escherichia coli, purification, renaturation, and bioactivity. The cDNA encoding survivin was cloned by RTPCR from breast cancer cell lines B-cap37. Expression vector pRSET-B-TAT-survivin (T34A) was constructed by PCR after survivin was mutated by PCR site-directed...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week